On September 13, U.S. Trade Representative Robert Lighthizer reportedly expressed a willingness to negotiate on several points of contention regarding the U.S.-Mexico-Canada Agreement (USMCA), including potentially reducing the 10-year period of intellectual property protection for biologic medicines. In response to this, the Pass USMCA Coalition is touting a memo penned by Former Department of Health and Human Services (HHS) Secretary Tommy Thompson aimed at “debunking the widespread myth that the USMCA will drive up drug prices.” Thompson, also a four-term governor of Wisconsin, now advises the Pass USMCA Coalition. Thompson’s memo focuses on three key arguments that he considers myths
As Lighthizer Negotiates on USMCA, Former HHS Secretary Warns Against Buying Into ‘Myths’
No Comments
Business
- Trade and Commerce in West Africa and How it Influences IP Rights
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- How Patents Helped Sprout the World’s First Plantable Pencil
- Patent Filings Roundup: Battle-Tested Off-Roading Patent Asserted; Jack Henry Battered Again
- When it Pays to Talk About Your Secrets
Recent Posts
- Other Barks & Bites for Friday, January 15: Copyright Office Issues Final Rule on Unmatched Musical Works Under MMA, $1 Billion Copyright Verdict Against Cox Communications Upheld, USPTO Publishes Report on China IP Filings
- USPTO Report Puts Chinese Innovation Growth in Context
- IFI Claims Reports: Patent Activity Increases Despite Pandemic, IBM Again Dominates Granted U.S. Patents, Samsung Leads Global 250
- Ericsson Wins Anti-Interference Injunction Against Samsung in Texas FRAND Case
- Supreme Court Will Review Doctrine of Assignor Estoppel